OBJECTIVE: To summarize the antihypertension guidelines recommended by WHO-ISH, JNC 7, the ADA, and the Hypertension in African Americans Working Group (HAAW Group) of the International Society on Hypertension in Blacks and evaluate the pharmacist's collaborative role in the management of hypertension by examining the results of programs designed to include pharmacist counseling.
METHODS: The relevant literature was evaluated and reviewed. Emphasis was placed on literature that evaluated strategies to improve BP control. RESULTS: Results from several programs and studies showed positive effects of pharmacist collaboration. A program that provided pharmacist academic detailing to physicians at 5 Veterans Affairs facilities resulted in significant increases in patients receiving β-blocker therapy or thiazide diuretics and angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy. Another study in which hypertensive patients received clinical services from pharmacists showed significant improvement in patients' knowledge of hypertension and its management and in patient adherence, and also showed a significant increase in the number of patients whose BP stayed in the normal range. A 6-month, controlled, single-blind, parallel-group study of 51 hypertensive patients showed significant improvements in BP control, quality of life, and overall patient satisfaction in the study group that received treatment through a primary care team that included pharmacists. Among patients at a Veterans Administration medical center, results suggested that the intervention of a clinical pharmacist improved documentation of drug therapy and estimated patient compliance. A study of the effectiveness of comanagement in 197 hypertensive patients with physician-pharmacist collaboration using an evidence-based, systematic approach showed that a significantly larger number of patients in the study group achieved BP control than in the control group.
CONCLUSIONS: The expanded role of clinical pharmacists in programs for evaluating, monitoring, and treating patients with hypertension can result in improved adherence to therapy and established guidelines. As members of interdisciplinary health care teams, pharmacists should utilize the JNC 7 guidelines and scientific evidence to consult with physicians about medications, design effective formularies, and collaborate with physicians in evaluating and comanaging patients with hypertension. ypertension is a major public health problem in developed nations. It is common, asymptomatic, readily detectable, and easily treatable-and it can lead to lethal complications if not treated. In the late 1960s and the 1970s, educational programs were developed to alert the population about the dangers of hypertension. As a result of those initiatives, a significant reduction in the prevalence of undiagnosed and/or untreated patients to about 25% was seen by the late 1980s, with a corresponding decline in associated cardiovascular mortality. 1 By the mid 1990s, however, the effects of educational programs began to decline. The population of undiagnosed patients with hypertension increased to nearly 33%, the decline in cardiovascular mortality plateaued, and the number of patients with chronic disease related to untreated or inadequately treated hypertension increased. Additionally, the prevalence of end-stage renal disease (ESRD) per million people increased from <100 in 1982 to >250 in 1995. Correspondingly, the prevalence of congestive heart failure in people aged 55 to 75 years more than doubled between 1976 and 1980 and 1988 and 1991. Although the pathogenesis of hypertension is now better understood, the etiology is still unknown in 90% to 95% of cases.
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Epidemiology of Hypertension
The prevalence of hypertension is predicated on the racial composition of the demographic groups studied and upon the defining criteria. In a white suburban population such as the one used in the Framingham Study, almost 20% of people in the study have blood pressure (BP) >160/95 mm Hg and almost 50% have a BP >140/90 mm Hg. Higher prevalence rates have been documented in the nonwhite population. In the female population, the prevalence of hypertension is related to age, with a significant rise in BP after age 50 that may be related to the hormonal changes occurring with menopause. The frequency ratio of hypertension in females versus males increases from 0.6 to 0.7 at age 30 to 1.1 to 1.2 by age 65.
H
Drug Therapy for Hypertension
There are 6 major classes of antihypertensive agents: thiazide diuretics, antiadrenergic agents, vasodilators, calcium channel blockers (CCBs), angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs). The rational use of an agent depends upon its site and mechanism of action as well as on the evidence that supports its use to decrease the rate of adverse outcomes related to hypertension. 2 The goal of drug therapy is to use these agents alone or in combination to restore arterial pressure to normal limits in order to avoid adverse patient outcomes as a result of the hypertension, while avoiding side effects from the medication. Because the exact mechanisms underlying arterial hypertension are often not understood completely on an individual patient basis, an empirical approach is used when treating most patients. The empirical approach considers efficacy, safety, cost, impact on the patient' s quality of life, ease of administration, and patient adherence. If antihypertensive agents are used in combination, they are usually chosen for their different mechanisms of action. Most patients are initially treated with a single agent, but instances of severe hypertension demonstrating an average diastolic pressure >130 mm Hg generally require intensive therapy using several agents.
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Antihypertension Guidelines
Two major authoritative groups have developed treatment guidelines to follow when patients are being managed: the World Health Organization-International Society of Hypertension (WHO-ISH) and the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). The approaches provided by these groups are similar and are based on the results of randomized clinical trials.
The Seventh Report of the JNC (JNC 7) recommends initial therapy with a diuretic for most patients with essential hypertension because diuretic agents have demonstrated a positive effect on morbidity and mortality. 2 WHO-ISH guidelines recommend beginning therapy with any of 6 classes of antihypertensive agents. The differences in recommendations reflect data from clinical trials that demonstrated a reduction in morbidity and mortality with long-acting CCBs versus placebo, with results similar to reports for diuretics and β-blockers. 1 The JNC 7 guidelines stress that aggressive BP control is essential to reduce morbidity and mortality. 2 Unfortunately, most patients are not at their BP goal. Poor BP control rates are even more of a problem for patients with diabetes (DM) and chronic kidney disease because their BP goals are even lower than for those patients with essential hypertension. 2 Managed care organizations will be increasingly expected to achieve high BP control rates in their members. Therefore, they must evaluate how pharmacists can be integrated in programs to achieve optimal improvement in BP control.
ss Objective
There are many important strategies, including interdisciplinary approaches, that can be used to implement BP guidelines. Two of the most effective strategies to achieve better adherence to BP guidelines involve physician-pharmacist collaboration or pharmacist-managed hypertension clinics. Pharmacists should use the new JNC 7 guidelines issued in May 2003 and other scientific evidence to educate prescribers, design effective formularies, and collaborate with physicians in direct management of patients with hypertension. This article will summarize the recommendations of the JNC guidelines as well as hypertension guidelines for special populations that should be promoted by pharmacists. This article will also describe how managed care pharmacists can contribute to hypertension management in a number of ways, including formulary management, academic detailing, population-based approaches to assess adherence to BP guidelines and BP control, and physician-pharmacist comanagement. The JNC 7 algorithm for the treatment of hypertension is presented in Figure 1 .
2 Therapy usually begins with lifestyle modifications (i.e., diet, weight loss, and exercise regimen). 2 The JNC 7 recommends that initial therapy for uncomplicated hypertension consist of a thiazide diuretic alone or in combination with another agent from one of the other classes of antihypertensives (e.g., CCBs, β-blockers, ARBs, ACE inhibitors). 2 If a patient' s BP is >20 mm Hg above the systolic goal or >10 mm Hg above the diastolic goal, initial therapy with 2 agents, either as separate prescriptions or in fixed-dose combinations, should be considered. 2 When patients have DM or chronic kidney disease, 2 or more antihypertensive agents will be needed to achieve BP goals of <130/80 mm Hg. Patient adherence to therapy is considered an important factor in the overall treatment of all hypertensive patients. 2 Initial therapy with more than one agent greatly increases the chances of reducing BP quickly. The advantage of multiple-agent therapy to treat hypertension is that combinations often produce greater BP reductions at lower doses and produce fewer adverse events. Use of generic drugs should be considered to reduce prescription costs. The cost of separate prescriptions for multiple generic agents may be less than for a nongeneric, fixed-dose combination drug. Beginning therapy with multiple agents, however, may increase the risk of hypotension, particularly in some older patients and in patients with DM and autonomic dysfunction. 
Blood Pressure Control in Special Populations
The strategies suggested in the JNC 7 are appropriate for the empiric management of most patients with essential hypertension. Therapy of special populations with hypertension may present particular challenges and require special attention in order to reduce hypertension-related morbidity and mortality in these vulnerable groups. Adequate BP control is difficult to achieve in special populations, particularly in African Americans and patients with DM.
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Patients With Diabetes Hypertension (>130/80 mm Hg) is a common comorbid condition in ~20% to 60% of all patients with DM and is often combined with factors such as obesity, ethnicity, and age. In type 2 DM, hypertension is frequently present as part of the metabolic syndrome of insulin resistance, which also includes central obesity and dyslipidemia. In type 1 DM, hypertension may be the harbinger of diabetic nephropathy. Elevated BP also increases the risk of both macrovascular and microvascular complications such as neuropathy, nephropathy, retinopathy, peripheral vascular disease, coronary heart disease, and stroke. 5 Hypertension in patients with DM is often a consequence of renal disease, which can be coincidental or part of the early malnutrition adaptation syndrome. Clinicians are undecided as to whether hypertension or renal disease comes first in patients with DM. In type 1 DM, the presence of microalbuminuria points to mild renal involvement. In type 2 DM, hypertension and microalbuminuria appear to develop in parallel. 4 Treatment guidelines recommended by the American Diabetes Association (ADA) are summarized in Table 1 and include lower BP targets for patients with DM (goal is <130/80 mm Hg) as well as ACE inhibitors or ARBs as cornerstones in the therapy of patients with DM and hypertension. 
African American Patients
In addition to a higher prevalence of hypertension, African Americans also have much higher rates of cardiovascular mortality, hypertension-related heart disease, congestive heart TABLE 1 failure, stroke, type 2 DM, hypertensive nephropathy, and ESRD. 6 Early diagnosis and persistent treatment of hypertension are required to address the resulting enormous burden of disease for African Americans. 6 Treatment recommendations for this population are based on the results of clinical studies, a synthesis of existing guidelines, pharmacologic options, and a consensus of the opinions of the Hypertension in African Americans Working Group (HAAW Group) of the International Society on Hypertension in Blacks. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALL-HAT), in which 36% of the participants were African American, evaluated antihypertensive agents and lipid-lowering agents. The African American Study of Kidney Disease and Hypertension (AASK) also contributed to treatment guidelines. In addition, 2 major hypertension management guidelines-JNC 7 and WHO-ISH-were considered for their relevance in the management of hypertension in African Americans. 6 Figure 2 summarizes the recommendations for the treatment of hypertension in African Americans. 6 Because African Americans carry a larger burden of risk for cardiovascular disease, it is imperative that they achieve adequate BP goals. Patients with type 2 DM (with or without nephropathy) or with nondiabetic renal disease with proteinuria characterized by >1 g/day should have a BP target goal of <130/80 mm Hg. 6 Most African Americans will require combination therapy to reach target BP levels. When 2 agents are used, the following combinations may be considered particularly effective: β-blocker/diuretic, ACE inhibitor/ diuretic, ACE inhibitor/CCB, or ARB/diuretic. New data suggest that thiazide diuretics, β-blockers, renin-angiotensin-aldosterone system (RAAS) blocking agents, and dihydropyridine CCBs reduce the risk of end-organ damage and poor outcomes. When there is a compelling indication to use a specific agent (e.g., β-blocker following myocardial infarction), race should not influence that decision. If the patient' s BP cannot be controlled with such a medication, the addition of a thiazide diuretic will frequently overcome any racial differences in antihypertensive response. 
The Pharmacist's Collaborative Role in the Management of Hypertension
Achieving BP goals begins with making lifestyle changes. At the outset, the physician and patient must agree on BP goals and the estimated time to reach those goals. That information should be recorded in the patient' s chart and discussed at each evaluation. Patients must be educated to accept that making lifestyle changes is essential to BP reduction. The role of the pharmacist in helping to achieve patient adherence has become a crucial component of the behavioral change necessary to achieve healthy BP goals. 2 The pharmacist' s unique position in the health care system provides a vantage point from which to assist with solving medication-related problems. Moreover, studies have demonstrated that when pharmacists are integrated into the hypertension management team, the control rates for BP improve and drug interactions, patient nonadherence, and costs decrease. 
Pharmacist-Physician Collaborative Models in the Treatment of Hypertension
Collaborative relationships between physicians and pharmacists are being developed to improve the management of hypertension. The physicians often refer selected patients to the pharmacist for follow-up between office visits. The pharmacist may measure BP, adjust dosages, and alter treatment regimens established by the physician. 7 A recent study demonstrated the value of the comanagement in hypertensive patients by using a collaborative effort between physicians and pharmacists. The object of the study was to compare the effectiveness of an evidence-based approach with the treatment of hypertensive care through comanagement of patients by primary care physicians and clinical pharmacists versus the usual care (UC) given to patients. Patients with uncontrolled hypertension were randomized to either a UC regimen that was managed only by primary-care physicians or to a physician-pharmacist comanagment (PPCM) group. All physicians received group and individual education, and they all took part in developing an evidence-based hypertension treatment algorithm. Physicians were given the names of the patients with documented elevated BP (≥140/≥90 mm Hg) for patients aged <65 years, (≥160/≥90 mm Hg) for patients aged ≥65 years. Patients randomized to the PPCM arm of the study had the additional input of a clinical pharmacist who provided patient education, made treatment recommendations, and provided follow-up. Medical records provided data such as visit costs, antihypertensive medications used, and BP readings. Figure 3 shows the results of the study. 8 A total of 197 patients with uncontrolled hypertension participated in the study. Both arms of the UC (-11/-8 mm Hg) and PPCM (-22/-7 mm Hg) study showed significant reductions in BP (P<0.01 for both groups). Results demonstrated that a significantly larger number of patients achieved BP control in the PPCM group (60%) than in the UC group (43%) (P = 0.02). The average visit costs per patient were significantly higher (P = 0.02) in the UC group ($195 per visit) than in the PPCM group ($160 per visit). 8 The investigators concluded that an evidence-based, systematic approach to the management of hypertension using both a physician and clinical pharmacist resulted in improved BP control and a reduced cost average per visit per patient. 8 
Academic Detailing to Improve Antihypertensive Prescribing Patterns
Studies have revealed that many physicians do not follow JNC recommendations on the treatment of hypertension. Likewise, they do not implement the recommendation made by the Medical Advisory Panel for the U.S. Department of Veterans Affairs (VA) that thiazide diuretics and β-blockers be used as first-line medications in the treatment of hypertension without comorbidities. 9 In an attempt to improve physician awareness of important prescribing guidelines, a program was established to train pharmacists as academic detailers. This pharmacist-physician interaction training was conducted at 5 VA medical facilities. The program comprised lectures, educational materials, provider profiling, and personal meetings with 25 to 50 providers. Prescribing patterns for hypertension were determined over two 6-month periods (March 1, 1998, to August 30, 1998, for baseline; March 1, 1999, to August 30, 1999, for follow-up). 9 Following this intervention program, the proportion of patients receiving CCBs decreased significantly from 43% to 38% (P<0.001), while the proportion of patients receiving β-blocker therapy or thiazide diuretics increased significantly from 58% to 64% (P<0.001). In hypertensive patients with DM, the proportion receiving an ACE inhibitor or ARB significantly increased from 72% to 76% (P<0.001).
Usual Care (UC) (x 99 patients) versus the physician-pharmacist comanagement (PPCM) (s 98 patients). The mean reduction in SBP was greater in PPCM than UC patients at 6, 9, and 12 months (P<0.01 for all comparisons
In hypertensive patients with congestive heart failure, the use of these agents significantly increased from 74% to 78% (P<0.001). An increase was also seen in the use of β-blockers in hypertensive patients with coronary artery disease (P<0.001 for change from baseline). Further, after academic detailing, the prescribing patterns more closely followed national guidelines. 9 Increased physician awareness of the value of following guidelines developed by expert national panels may therefore help improve both the quality and the economy of antihypertensive treatment.
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Expanded Roles for Community Pharmacists Community pharmacists can become links between patients and physicians. Often, the pharmacist is the only member of the health care team with access to information about all of the patient' s medications and so may be the only person aware of concurrent therapies prescribed by multiple physicians. The pharmacist can provide the physician with information about the number of prescription refills during a year-indicating a measure of adherence. Physicians may use this information when altering management strategies or making future treatment decisions. Medication costs to patients are always an important issue, and the pharmacist can assist in the development of cost-effective strategies that use JNC guidelines and recommendations from other recent consensus panels. 7 Several studies have suggested that pharmacists can provide hypertensive patients with many services that were previously offered solely by physicians. Since hypertension is a disorder managed mainly by pharmacologic means, the involvement of trained, motivated, community pharmacists should benefit many hypertensive patients. One 5-month study demonstrated that the clinical services provided to hypertensive patients by a clinical pharmacist resulted in a significant improvement (P<0.001) in patients' knowledge of hypertension and management, a significant increase in patient medication adherence (P<0.001), and a significant increase in the number of patients whose BP stayed within normal range during the study (P<0.001). The unique design of this study was that it included a baseline period, intervention period, and an evaluation after the intervention was discontinued. 10 Data from this study conducted in 49 patients include the following:
• Scores obtained from a 21-question test designed to evaluate the patients' knowledge of hypertension and its management showed that the number of correct answers increased from 259 prestudy to 436 poststudy in the group that 
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• During the study period, the percentage of study patients who were compliant with drug therapy (defined as administration of 90% to 110% of prescribed doses) increased from 25% pretest to 79% in the study group compared with an increase from 16% to 17% in the control group. Both groups reverted to their pretest scores after the study. This latter finding indicates that simply implementing an intervention in hypertension is not sufficient for long-term results and that continued patient education, follow-up, and management are important to continue to achieve BP control.
• The percentage of study patients who were normotensive (had an average DBP <90 mm Hg on 2 consecutive meetings) increased from 20% prestudy to 79% during the study period in the group that had the services of a clinical pharmacist but declined from 44% to 20% in the control group. Those percentages declined to 42% in the study group and to 14% in the control group after the study.
• Average BP rates in the study group were 157/99 mm Hg prestudy, 146/90 mm Hg during the study, and 149/97 mm Hg poststudy in the study group. In the control group, average BP rates were 163/93 mm Hg, 166/101 mm Hg, and 168/103 mm Hg, respectively.
Data from the results of another study indicated that when community pharmacists were trained and participated as members of the primary-care treatment team, significant (P<0.05) improvements in patient satisfaction, BP control, and quality of life (QOL) were achieved. Known as the Taylorville Study, this was a controlled, single-blind, parallel-group study that evaluated pharmaceutical care provided to hypertensive patients and assessed the quality of care delivered by a model, interdisciplinary practice. 11 The primary objective of the Taylorville Study was assessed by determining outcome variables at 6 months compared with baseline in 25 hypertensive patients randomly assigned to a study group. The control group consisted of 26 patients who were evaluated to determine if outcome variables remained constant from baseline to 6 months. Baseline SBP (151 mm Hg) was significantly reduced in the study group (P<0.001) at 6 months (140 mm Hg). DBP was also significantly lower at 2, 4, and 5 months with baseline. Peer-rated review of prescribing data indicated a significant (P<0.01) improvement in the appropriateness of the BP regimen, increasing from 8.7 ± 4.7 to 10.9 ± 4.5 in the study group, but showing no change in the control group. This study also revealed that QOL scores improved significantly (P<0.05) in the study group after 6 months but did not change significantly in the control group. Overall, patient satisfaction scores were consistently higher in the study group at the end of the clinical trial. The investigators concluded that significant improvements in BP control, QOL, and overall patient satisfaction were accomplished when community pharmacists were trained and included as part of the primary-care team.
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The Pharmacist's Role in Helping to Ensure Patient Adherence Patient nonadherence is a serious obstacle to the effective treatment of many acute and chronic disorders. Successful treatment and outcome of a chronic disease such as hypertension depend on many factors, including resources (e.g., funds, space, people), avoidance of serious adverse events, patient adherence with treatment plans, and the availability of effective therapies. The JNC 7 recommendations for supporting and sustaining patient treatment regimens are shown in Table 2 . 2 The pharmacist is often in an ideal position to assist with patient education and monitoring to improve medication and lifestyle adherence. As noted above, studies suggest that using the clinical pharmacist to monitor BP improves patient adherence, drug documentation, and disease control. 12 The results of a study among patients who received clinical pharmacy services at a VA medical center suggested that the intervention of a clinical pharmacist improved documentation of drug therapy and estimated patient compliance. Of 81 patients in the control group, 33% were judged to be compliant; of 113 patients in the study group, 85% were judged to be compliant. At 4 years, follow-up compliance in the study group was 88%, and BP was controlled in 90% of patients, while only 29% of patients in the control group had controlled hypertension. 12, 13 ss Results
The Pharmacist's Evolving Role in Health Care Delivery
The expanded role of pharmacists in integrated health care delivery systems (e.g., VA medical centers, the Indian Health Service, and staff-model managed care organizations) includes participation in primary care teams. In this capacity, pharmacists assist with drug selection and monitoring, and they consult on the development of therapy guidelines and treatment pathways. 7 Additionally, more than 30 states now allow pharmacists to manage patients through collaborative agreements with physicians, and the majority of those collaborative arrangements are in integrated health systems. 7 Another area in which the pharmacist' s role is emerging is in physician office practices. Studies have shown that the long-term benefit of including a clinical pharmacist in a practice' s program for patients with hypertension is cost effective. Primary savings are realized in fewer hospitalizations and reduced morbidity resulting from inadequately controlled BP. 7 In the community setting, the role of the pharmacist continues to evolve. Local pharmacists now assist physicians with monitoring patients who have hypertension-helping to improve patient adherence to therapy, reduce adverse events, and improve BP control. Many community-based pharmacists screen for new or uncontrolled hypertension and refer patients to physicians. 7 Given that almost every community has a pharmacy, 7 that most people use only 1 pharmacy, 7 and that consumer confidence in pharmacists is very high 7 -the expanded role of the pharmacist as a member of primary-care teams can be a valuable asset for patients and physicians alike. As an integral part of an interdisciplinary team, pharmacists have an important contribution to make in achieving JNC goals for controlling hypertension. 7 ss
Conclusions
Studies have demonstrated that the role of the pharmacist in the management of chronic diseases such as hypertension has increased in recent years. The pharmacist' s role includes ensuring that recommendations provided by national guidelines such as the JNC 7 and the ADA in the treatment of hypertension are followed. It has been shown that when pharmacists are closely involved in the comanagement of patients with hypertension, greater reductions in BP are recorded, goal BPs are reached and maintained more frequently, patient QOL is improved, and more patients remain adherent to their medication regimens. In addition, when pharmacists become an integrated part of the primary care team, overall costs of therapy are better contained without sacrificing the quality of care. Pharmacist involvement in rural clinics, VA medical centers, and community hospitals has increased, and pharmacist participation has been positively acknowledged by medical staff and patients. Studies have also demonstrated that clinical pharmacy services are highly beneficial and enhance the long-term care given to hypertensive patients. 
